secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-266916
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences Q3 net loss $29.9M; cash $274.9M; dabogratinib trials on track
-------------------------------------------------------------------------------

- Cash, equivalents, and marketable securities of $274.9M as of Sep 30, 2025; runway through at least 2027.
- Q3 net loss $29.9M vs $24.0M in Q3 2024; R&D spend $25.5M (up from $22.7M) on trial initiations.
- First patients dosed in Phase 2 achondroplasia (BEACH301) and NMIBC (SURF302) studies; interim data expected 2026.
- FDA cleared IND for dabogratinib in low-grade upper tract urothelial carcinoma (SURF303); Phase 2 start in 2026.
- Upcoming milestones: SURF302 3-month CR data in 1H 2026; BEACH301 safety sentinel results in 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312525266916/0001193125-25-266916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312525266916/tyra-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-266916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer